BLTE - חוב כולל להון Belite Bio, Inc.

Belite Bio, Inc (BLTE) is an innovative biotech company developing a unique treatment for Stargardt disease to capture a monopoly segment of the ophthalmology market. The share price history on the GURU.Markets platform demonstrates a dependence on the outcomes of retinal degeneration drug trials and regulatory verdicts, with the metric standing at 0.00. The company's production facilities are fully certified and are currently focused on the manufacture of pilot drug batches.

The total debt-to-equity ratio measures the proportion of borrowed liabilities relative to shareholders' equity, determining the degree of financial leverage and the stability of the balance sheet structure. By analyzing changes in the leverage ratio, an investor assesses bankruptcy risk, which is critical for Belite Bio, Inc (BLTE), whose capital expenditures to complete Phase 3 trials have yet to generate commercial revenue.